Ashton Thomas Securities LLC trimmed its position in shares of McKesson Corporation (NYSE:MCK - Free Report) by 17.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,856 shares of the company's stock after selling 1,497 shares during the period. McKesson accounts for approximately 1.1% of Ashton Thomas Securities LLC's investment portfolio, making the stock its 20th biggest position. Ashton Thomas Securities LLC's holdings in McKesson were worth $5,636,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. J.W. Cole Advisors Inc. raised its position in McKesson by 35.3% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company's stock worth $3,931,000 after purchasing an additional 1,329 shares during the period. Cullen Investment Group LTD. grew its stake in McKesson by 550.4% in the 4th quarter. Cullen Investment Group LTD. now owns 4,670 shares of the company's stock worth $3,811,000 after acquiring an additional 3,952 shares in the last quarter. Private Wealth Partners LLC grew its stake in McKesson by 5.6% in the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company's stock worth $24,598,000 after acquiring an additional 1,682 shares in the last quarter. AlphaQuest LLC grew its stake in McKesson by 91.2% in the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company's stock worth $1,365,000 after acquiring an additional 843 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in McKesson by 12.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company's stock worth $255,438,000 after acquiring an additional 36,451 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on MCK. Morgan Stanley restated an "overweight" rating and issued a $966.00 target price on shares of McKesson in a research note on Thursday, January 29th. Evercore restated an "outperform" rating on shares of McKesson in a research note on Thursday, March 5th. Wells Fargo & Company upped their target price on shares of McKesson from $914.00 to $925.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 5th. UBS Group dropped their price objective on shares of McKesson from $1,012.00 to $1,000.00 and set a "buy" rating on the stock in a research note on Wednesday, April 22nd. Finally, TD Cowen increased their price objective on shares of McKesson from $1,000.00 to $1,012.00 and gave the company a "buy" rating in a research note on Thursday, February 5th. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $972.27.
Get Our Latest Research Report on MCK
McKesson Trading Down 0.1%
NYSE MCK opened at $814.69 on Friday. The company has a fifty day simple moving average of $894.86 and a two-hundred day simple moving average of $859.16. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00. The stock has a market cap of $99.79 billion, a P/E ratio of 23.43, a P/E/G ratio of 1.18 and a beta of 0.35.
McKesson (NYSE:MCK - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm had revenue of $106.16 billion during the quarter, compared to analysts' expectations of $105.98 billion. During the same quarter last year, the company posted $8.03 earnings per share. The firm's revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, sell-side analysts forecast that McKesson Corporation will post 39.02 earnings per share for the current year.
McKesson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson's dividend payout ratio (DPR) is presently 9.43%.
Insider Activity
In other news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $955.00, for a total transaction of $313,240.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michele Lau sold 2,725 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the sale, the executive vice president directly owned 3,247 shares in the company, valued at approximately $3,214,530. The trade was a 45.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,592 shares of company stock worth $3,518,555 over the last 90 days. Company insiders own 0.08% of the company's stock.
McKesson Company Profile
(
Free Report)
McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.
The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.
Featured Stories
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider McKesson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.
While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report